| Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data JM Dennis, BM Shields, WE Henley, AG Jones, AT Hattersley The lancet Diabetes & endocrinology 7 (6), 442-451, 2019 | 385 | 2019 |
| Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, March to June 2020 JM Dennis, AP McGovern, SJ Vollmer, BA Mateen Critical care medicine 49 (2), 209-214, 2021 | 221 | 2021 |
| Type 2 diabetes and COVID-19–related mortality in the critical care setting: a national cohort study in England, March–July 2020 JM Dennis, BA Mateen, R Sonabend, NJ Thomas, KA Patel, AT Hattersley, ... Diabetes care 44 (1), 50-57, 2021 | 197 | 2021 |
| Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and … JM Dennis, WE Henley, MN Weedon, M Lonergan, LR Rodgers, ... Diabetes care 41 (9), 1844-1853, 2018 | 125 | 2018 |
| Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes … AL Lynam, JM Dennis, KR Owen, RA Oram, AG Jones, BM Shields, ... Diagnostic and prognostic research 4, 1-10, 2020 | 118 | 2020 |
| Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017 HJ Curtis, JM Dennis, BM Shields, AJ Walker, S Bacon, AT Hattersley, ... Diabetes, Obesity and Metabolism 20 (9), 2159-2168, 2018 | 96 | 2018 |
| Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short-and long-term glycemic response to DPP-4 inhibitor therapy JM Dennis, BM Shields, AV Hill, BA Knight, TJ McDonald, LR Rodgers, ... Diabetes care 41 (4), 705-712, 2018 | 87 | 2018 |
| Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment JM Dennis Diabetes 69 (10), 2075-2085, 2020 | 86 | 2020 |
| Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010–2017 JM Dennis, WE Henley, AP McGovern, AJ Farmer, N Sattar, RR Holman, ... Diabetes, Obesity and Metabolism 21 (7), 1576-1584, 2019 | 85 | 2019 |
| Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine DK Tobias, J Merino, A Ahmad, C Aiken, JL Benham, D Bodhini, AL Clark, ... Nature medicine 29 (10), 2438-2457, 2023 | 80 | 2023 |
| Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes ATN Nair, A Wesolowska-Andersen, C Brorsson, AL Rajendrakumar, ... Nature Medicine 28 (5), 982-988, 2022 | 79 | 2022 |
| Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation AP McGovern, M Hogg, BM Shields, NA Sattar, RR Holman, ER Pearson, ... BMJ Open Diabetes Research and Care 8 (1), e001238, 2020 | 67 | 2020 |
| Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years A Lynam, T McDonald, A Hill, J Dennis, R Oram, E Pearson, M Weedon, ... BMJ open 9 (9), e031586, 2019 | 67 | 2019 |
| Risk of anemia with metformin use in type 2 diabetes: a MASTERMIND study LA Donnelly, JM Dennis, RL Coleman, N Sattar, AT Hattersley, ... Diabetes Care 43 (10), 2493-2499, 2020 | 62 | 2020 |
| The association between mechanical ventilator compatible bed occupancy and mortality risk in intensive care patients with COVID-19: a national retrospective cohort study H Wilde, T Mellan, I Hawryluk, JM Dennis, S Denaxas, C Pagel, A Duncan, ... BMC medicine 19, 1-12, 2021 | 52 | 2021 |
| Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study BM Shields, JM Dennis, CD Angwin, F Warren, WE Henley, AJ Farmer, ... Nature medicine 29 (2), 376-383, 2023 | 39 | 2023 |
| Heterogeneity of diabetes: β-cells, phenotypes, and precision medicine: proceedings of an international symposium of the Canadian Institutes of Health Research’s Institute of … WT Cefalu, DK Andersen, G Arreaza-Rubín, CL Pin, S Sato, CB Verchere, ... Diabetes 71 (1), 1-22, 2022 | 36 | 2022 |
| Hospital bed capacity and usage across secondary healthcare providers in England during the first wave of the COVID-19 pandemic: a descriptive analysis BA Mateen, H Wilde, JM Dennis, A Duncan, N Thomas, A McGovern, ... BMJ open 11 (1), e042945, 2021 | 35 | 2021 |
| The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation AP McGovern, NJ Thomas, SJ Vollmer, AT Hattersley, BA Mateen, ... Diabetologia 64 (5), 1184-1186, 2021 | 28 | 2021 |
| Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study JM Dennis, KG Young, AP McGovern, BA Mateen, SJ Vollmer, ... The Lancet Digital Health 4 (12), e873-e883, 2022 | 22 | 2022 |
